Canurta Showcases Healthy Aging Innovations on Global Stage and Advances Clinical Formulations

Canurta CEO attends Hevolution Foundation's Inaugural Global Healthspan Summit in Riyadh, Saudi Arabia between Nov 29-Nov 30

With the global population over 60 expected to double to 2 billion by 2050, increasing healthy human healthspan is one of the most urgent issues of our time and could generate savings of $40 trillion per year.

Canurta aims to impact the healthy aging market with new therapeutics to target inflammation in chronic diseases along with natural health products to support prevention and active living.

Hevolution Foundation is investing in grants for aging research and pioneering impact investments in early-stage biotech with an annual budget of up to $1 billion.

Learn More

Canurta Selected to Present at OBIO Investment Summit Feb 14-16

Canurta is proud to be selected to present at the Ontario Bioscience Innovation Organization (OBIO) Investment Summit that has raised more than $1.6B for participating companies since 2018.

The focus is on health science companies commercializing products and services in therapeutics, medical devices, diagnostics, digital health and health IT.

Canurta Presents at Bio-Europe in Munich

Following an invitation from the Government of Ontario, Canurta joined BIOTECanada, the national voice for Canada’s biotechnology sector and the Mississauga Economic Development Office in Munich at Bio-Europe, the largest gathering of biopharma professionals in Europe between Nov 6-8.

Canurta CEO Akeem Gardner engaged in one-on-one meetings, fostering collaboration and networking within the global life sciences community.

Canurta's November Milestones

Research & Development

New Formulation for Sublingual Strips: We have developed a promising formulation for sublingual strips to deliver our polyphenol extract. We are also performing preliminary toxicity assays for the ALS formulation (CNR 401) in our zebrafish model which will lead into efficacy trials in December.

Manufacturing

Recent Visit to InnoFibre: Production Lead, Cameron Parry, visited Canurta's manufacturing research partner, Innofibre, in Trois-Rivieres. Research continues to move extremely well, with optimization of our extraction technology on the forefront.

Bioinformatics

Computational Tools for ALS and ARDS Treatment Development: With the collaboration of our R&D experts, our team identified methods and initiated research on harnessing computational tools for meticulous data analysis of ALS and ARDS positive treatment results to optimize the application of our lead molecules across these different therapeutic areas and enhance the effectiveness of future clinical trials.